Summary
Eli Lilly & Company (LLY) filed an 8-K on October 20, 2005, to report its financial results for the third quarter and the first nine months of 2005. The filing primarily serves to attach a press release detailing these results and the company's financial outlook for the fourth quarter and full year 2005. A key aspect of the report is the company's use of non-GAAP financial measures, such as adjusted net income and adjusted earnings per share (EPS), to provide a clearer view of ongoing operational performance and facilitate year-over-year comparisons. These adjusted measures exclude significant one-time items like charges for acquired in-process R&D, asset impairments, product liability, and restructuring. The company also provided pro-forma adjustments to 2004 results to reflect the adoption of new accounting standards for share-based payments starting in 2005, enabling more meaningful comparisons. Investors are advised to consider these non-GAAP measures alongside, not as a substitute for, GAAP figures to gain a comprehensive understanding of Lilly's financial condition and operational trends.
Key Highlights
- 1LLY reported third quarter and nine-month 2005 financial results via an 8-K filing on October 20, 2005.
- 2The company issued forward-looking financial expectations for Q4 and full-year 2005.
- 3Lilly is utilizing non-GAAP financial measures (adjusted net income, adjusted EPS) to present operational performance.
- 4Adjusted results exclude significant items such as charges for acquired R&D, asset impairments, product liability, and restructuring.
- 5Pro-forma adjustments were made to 2004 EPS to align with the adoption of new share-based payment accounting standards in 2005.
- 6The purpose of these adjustments is to provide more meaningful period-over-period comparisons and highlight ongoing operational trends.
- 7The press release detailing these results is included as Exhibit 99 to the 8-K filing.